top of page
  • landaulabnyu

Landau Lab collaborates with Carisma Therapeutics!

Updated: Nov 7, 2020

CARISMA Therapeutics Inc. now shares the license to use the vpx lentiviral vector created in our lab to facilitate the development of chimeric antigen receptor macrophages (CAR-M) targeting human epidermal growth factor receptor 2 (HER2), for the treatment of solid tumors.

Check out the official press release here.

64 views0 comments

Recent Posts

See All


bottom of page